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High-throughput mutational screening adds 
clinically important information in myelodysplastic
syndromes and secondary or therapy-related acute
myeloid leukemia
Recurrent mutations are implicated in the prognosis of
myeloid malignancies and are likely to be incorporated into
the next WHO classification. We evaluated a pooling
approach for cost-effective targeted sequencing in combi-
nation with a clinically accredited method for validating
point mutations, Sequenom®. We found the pooling strate-
gy adequate for detecting clonal mutations, but not sensi-
tive enough to confidently detect subclonal mutations. Our
data indicate that targeted sequencing adds prognostic
information to existing risk scores in myelodysplastic syn-
dromes (MDS), mixed myeloproliferative/MDS neoplasms
(MDS-MPN) and acute myeloid leukemia (AML). 
More than one-third of patients with MDS have higher-
risk disease with poor overall survival and a high rate of
progression to AML.1 Several clinical trial programs, there-
fore, include higher-risk MDS in current protocols for
AML.2,3 Moreover, based on clinical and cytogenetic char-
acteristics, a biological similarity between higher-risk MDS
and poor prognosis AML has been suggested. Poor-risk
cytogenetic abnormalities encompassing complete or par-
tial loss of chromosome 5, 7, and 17, and complex kary-
otype are found in both diseases; but outside this group,
the cytogenetic pattern differs markedly between MDS and
AML.4 FLT3, NPM1, CEBPA and KIT mutations are inte-
grated in the current WHO classification for AML, but are
rarely mutated in MDS, or secondary or therapy-related
AML.5 
Consecutive adult patients were enrolled in the MDS
and AML registers at the Karolinska University Hospital
and diagnostic bone marrow (BM) samples were
biobanked. The MDS cohort (n=100) consisted of patients
with MDS and MDS-MPN (n=100) and the AML cohort
(n=92) of patients with AML evolving from MDS (MDS-
AML) or MPN (MPN-AML), therapy-related AML (tAML),
and AML with MDS like cytogenetics (Online
Supplementary Appendix and Online Supplementary Table S1).
First-line treatment for both cohorts followed current ther-
apeutic guidelines developed by the European
LeukemiaNet project.6,7 Eighteen patients (7 MDS and 11
AML) underwent allogeneic stem cell transplantation.
DNA samples from 20 healthy subjects were used as con-
trols. The study was approved by the local ethics commit-
tee and samples were obtained after informed consent.
Categorical data were compared using Fisher’s exact test,
survival was estimated using Kaplan-Meier method and
compared using the log rank test, and Cox proportional
hazards model was used for uni- and multivariable analy-
ses. Variables included in the model for MDS were muta-
tions found to be significant in the univariable analyses
(Online Supplementary Table S2) together with age, sex and
IPSS-R classification. In the corresponding model for AML,
IPSS-R was replaced by the cytogenetic risk group. Two-
sided P values with a significance level of 0.05 were used in
all analyses.8
Halogenomics target amplification technology was
applied to amplify all exons of 22 selected recurrently
mutated genes9,10 from BM mononuclear cell DNA (Online
Supplementary Appendix). To analyze samples in a high-
throughput and cost effective way we used a pooling
approach with 10 samples per pool. A total of 22 pools
were defined by 6 bp barcoding and samples were
sequenced in 2 Illumina Hiseq2000 sequencing system
using a 100 bp paired end protocol. Sequencing data were
filtered based on the barcodes of each pool and aligned to
the human genome reference hg19 with BWA version
0.5.9-r16.11Only variants covered by 4 or more reads were
considered for variant calling, and reads with more than 4
mismatches were disregarded. Finally, variants were anno-
tated with ANNOVAR version 2011-11-28.12 Non-synony-
mous variants in protein coding regions (232 in total) were
selected and analyzed by Sequenom® technology. In addi-
tion, we analyzed hotspot mutations in three splicing factor
genes, SF3B1, SRSF2 and U2AF1. 
The median sequencing coverage in each pool was 4658
and we detected 261 variations with functional effects in
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Figure 1. Distribution of mutations and cytogenetic aberrations in 100 patient samples with myelodysplastic syndromes (MDS) and 92
samples with acute myeloid leukemia (AML). Each column represents one patient. The colors represent different subgroups of the dis-
eases. *Denotes patients with MDS who subsequently progressed to AML and AML with a morphologically identified preceding MDS
phase. ¤Denotes patients with normal karyotype and no mutation. aberr.: aberration; MK: monosomal karyotype; TSG: tumor suppressor
gene. 
protein coding regions of which 41 variations already were
reported as germ-line polymorphisms and were excluded
from further analysis. Of the 232 variations analyzed by
Sequenom®, 85 were identified as real mutations and were
included in further analysis. As we noticed a TP53 and
ASXL1 mutational frequency lower than expected in
patients with del(5q) deletions and tAML, we performed
re-sequencing of TP53 in 47 patients (all 20 del(5q) MDS,
18 other MDS and 9 AML samples). We discovered two
additional TP53 mutations and three additional ASXL1
mutations. In 3 of these samples, the allele burden was
20% or less. Adding these mutations to the statistical
model did not change outcome data, which remained
based on the whole cohort.
Sixty-one percent of MDS and 50% of AML patients had
mutations in at least one gene, and 22% and 15%, respec-
tively, had mutations in more than one gene. In the MDS
cohort, the most frequently mutated genes were SF3B1,
TET2, SRSF2 and IDH2 (Figure 1), confirming the results of
two recent large studies of MDS.9,10 In the AML cohort,
TET2, SRSF2, U2AF1 and IDH2 were the most frequently
mutated genes (Figure 1 and Online Supplementary S3).
SF3B1 mutations dominated in RARS/RCMD-RS, while
mutations in epigenetic regulators dominated in other
MDS subtypes. As expected, patients with 5q- syndrome
had the lowest frequency of gene mutations, 21%. TET2
mutations were observed more frequently in CMML than
in MDS (60% vs. 9%; P=0.001) (Figures 1 and 3A), with
SRSF2 being the second most common mutation.13
Within the AML cohort, mutational frequencies varied
significantly between different subgroups, which indicates
that these patients are more heterogeneous than previously
thought (Figure 1). MDS-AML shared features with higher
risk MDS with mutations predominantly in epigenetic and
splicing genes, and with a minor proportion of mutations in
signaling genes and oncogenes. By contrast, AML with
MDS-like cytogenetics showed lower frequency of splice
factor and epigenetic mutations (Figure 1). The mutational
pattern of MPN-AML differed from the other AML by a
higher incidence of signaling and oncogenic mutations.
Interestingly, 87% of patients with tAML showed cytoge-
netic abnormalities, while the mutational rate was relative-
ly low (33%), indicating that chromosomal aberrations
constitute the main driver of disease in these patients.
However, albeit only 13% of tAML carried del(5q), an
underestimation of TP53 mutations cannot be excluded. In
order to discover mutations associated with transformation
from MDS to AML in MDS, we grouped MDS patients
with subsequent progression to AML with AML patients
with morphologically identified preceding MDS and com-
pared them with MDS without AML progression (Figure
2). The only gene that was positively associated with pro-
gression was U2AF1 (3 of 11 MDS with AML progression
and 5 of 28 MDS-AML, compared to 4 of 89 MDS without
transformation; P=0.008). No other mutation was signifi-
cantly associated with transformation and our data point
towards a distinct prognostic role of U2AF1. We also con-
firm the previously described negative correlation between
SF3B1 mutation and risk of AML progression (20 of 89
MDS without transformation versus 1 of 34 with AML
transformation; P=0.004).9,10
We assessed the additive prognostic value of recurrent
mutations (Figure 3). As SF3B1mutations alone were asso-
ciated with a favorable prognosis both in the univariable
analysis and in previous studies,14 patients were grouped as
no mutations or SF3B1 mutation only versus any mutation
except SF3B1. Furthermore, MDS patients were grouped
according to the Revised International Prognostic Score
System (IPSS-R) in IPSS-R very low, low and intermediate
risk versus high and very high risk. Overall survival (OS)
was better in patients with no or SF3B1mutations than in
patients with other mutations, and the difference was more
pronounced in the low/intermediate risk group (P<0.001)
(Figure 3A). Similar results were obtained when OS was
replaced by progression-free survival (P<0.001) (Figure 3B).
This strongly supports the additional prognostic value of
mutational screening in addition to IPSS-R in MDS. 
Acute myeloid leukemia patients were grouped based on
cytogenetic risk assessment15 in low risk + intermediate risk
(n=40) versus high risk (n=52) and then further divided into
mutated and non-mutated patients. No AML patient had
SF3B1mutation only. As illustrated in Figure 3C, the muta-
tional status did not contribute to OS in high-risk AML
patients. However, the OS of low + intermediate risk
patients with mutations was lower than that of patients
without mutations, indicating that gene mutations per se
may influence disease pathogenesis (Figure 3C).
Finally, a Cox proportional hazards model was used to
analyze OS in the MDS cohort (Online Supplementary Table
S2). In univariable analysis, SF3B1 significantly correlated
with better, and SRSF2, IDH2, U2AF1 and RUNX1 with
worse survival. After adjusting for sex, age and IPSS-R, only
SF3B1 and U2AF1 remained independent prognostic fac-
tors [mutated vs. non-mutated (HR 0.34, 95%CI: 0.14-0.82)
and (HR 2.78, 95%CI: 1.07-7.25)]. In the corresponding
model for AML, TP53 and NRAS showed a significant cor-
relation with worse survival, even after adjusting for sex,
age and cytogenetic risk, although the number of patients
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Figure 2. Proportion of patients with a
certain gene mutation that did or did
not progress from myelodysplastic
syndromes to acute myeloid
leukemia. Blue bars consist of MDS
with subsequent progression to AML
and AML with an identified preceding
diagnosis of MDS (n=39). Red bars
consist of all cases from the
myelodysplastic syndromes cohort
without a known progression to acute
myeloid leukemia (n=89). Median fol-
low up was 57.3 months (9.7–113,
SD±27.0) for MDS and 88.5 months
(27.6–190, SD ±40.5) for acute
myeloid leukemia patients. 
were very few entailing wide confidence intervals.
In conclusion, mutational screening by targeted sequenc-
ing provides important clinical information for MDS and
AML and will develop to become a prognostic tool in cen-
ters managing these disorders. Targeted sequencing will
constitute a cornerstone in patient management during the
next years. While the pooling approach is adequate for
detecting clonal mutations, important subclonal mutations,
such as TP53 and ASXL1 may be missed by this strategy.
Sequenom® methodology, or equivalent quick genotyping
tests, may prove to be a rapid and cost-effective method to
detect hotspot mutations.
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Figure 3. Survival according to risk classification combined with
mutational status. (A) Survival in IPSS-R very low+intermediate
risk MDS versus high+very high risk myelodysplastic syndromes
(MDS) with or without the presence of any mutation other than
SF3B1. (B) Acute myeloid leukemia (AML)-free survival in IPSS-R
very low+intermediate risk myelodysplastic syndromes (MDS) ver-
sus high+very high risk myelodysplastic syndromes (MDS) with or
without the presence of any mutation other than SF3B1. (C)
Survival in low+intermediate cytogenetic risk acute myeloid
leukemia (AML) versus high cytogenetic risk acute myeloid
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